Cargando…
Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
AIMS: Tacrolimus is a critical dose drug and to avoid under‐ and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug‐related toxicity occur despite whole‐blood tacrolimus pre‐dose concentrations ([Tac](blood)) being on target. Monitoring tacrolimus concentrati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056738/ https://www.ncbi.nlm.nih.gov/pubmed/33025649 http://dx.doi.org/10.1111/bcp.14585 |
_version_ | 1783680710054248448 |
---|---|
author | Francke, Marith I. Hesselink, Dennis A. Li, Yi Koch, Birgit C.P. de Wit, Lucia E.A. van Schaik, Ron H.N. Yang, Lin Baan, Carla C. van Gelder, Teun de Winter, Brenda C.M. |
author_facet | Francke, Marith I. Hesselink, Dennis A. Li, Yi Koch, Birgit C.P. de Wit, Lucia E.A. van Schaik, Ron H.N. Yang, Lin Baan, Carla C. van Gelder, Teun de Winter, Brenda C.M. |
author_sort | Francke, Marith I. |
collection | PubMed |
description | AIMS: Tacrolimus is a critical dose drug and to avoid under‐ and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug‐related toxicity occur despite whole‐blood tacrolimus pre‐dose concentrations ([Tac](blood)) being on target. Monitoring tacrolimus concentrations at the target site (within peripheral blood mononuclear cells; [Tac](cells)) may better correlate with drug‐efficacy. The aim of this study was to (1) investigate the relationship between [Tac](blood) and [Tac](cells), (2) identify factors affecting the tacrolimus distribution in cells and whole‐blood, and (3) study the relationship between [Tac](cells) and clinical outcomes after kidney transplantation. METHODS: A total of 175 renal transplant recipients were prospectively followed. [Tac](blood) and [Tac](cells) were determined at Months 3, 6 and 12 post‐transplantation. Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T, and CYP3A5 6986G>A. Data on rejection and tacrolimus‐related nephrotoxicity and post‐transplant diabetes mellitus were collected. RESULTS: Correlations between [Tac](blood) and [Tac](cells) were moderate to poor (Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The [Tac](cells)/[Tac](blood) ratio was stable over time in most patients (median intra‐patient variability 39.0%; range 3.5%–173.2%). Age, albumin and haematocrit correlated with the [Tac](cells)/[Tac](blood) ratio. CYP3A5 and CYP3A4 genotype combined affected both dose‐corrected [Tac](blood) and [Tac](cells). ABCB1 was not significantly related to tacrolimus distribution. Neither [Tac](blood) nor [Tac](cells) correlated with clinical outcomes. CONCLUSIONS: The correlation between [Tac](blood) and [Tac](cells) is poor. Age, albumin and haematocrit correlate with the [Tac](cells)/[Tac](blood) ratio, whereas genetic variation in ABCB1, CYP3A4 and CYP3A5 do not. Neither [Tac](blood) nor [Tac](cells) correlated with clinical outcomes. |
format | Online Article Text |
id | pubmed-8056738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80567382021-04-23 Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients Francke, Marith I. Hesselink, Dennis A. Li, Yi Koch, Birgit C.P. de Wit, Lucia E.A. van Schaik, Ron H.N. Yang, Lin Baan, Carla C. van Gelder, Teun de Winter, Brenda C.M. Br J Clin Pharmacol Original Articles AIMS: Tacrolimus is a critical dose drug and to avoid under‐ and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug‐related toxicity occur despite whole‐blood tacrolimus pre‐dose concentrations ([Tac](blood)) being on target. Monitoring tacrolimus concentrations at the target site (within peripheral blood mononuclear cells; [Tac](cells)) may better correlate with drug‐efficacy. The aim of this study was to (1) investigate the relationship between [Tac](blood) and [Tac](cells), (2) identify factors affecting the tacrolimus distribution in cells and whole‐blood, and (3) study the relationship between [Tac](cells) and clinical outcomes after kidney transplantation. METHODS: A total of 175 renal transplant recipients were prospectively followed. [Tac](blood) and [Tac](cells) were determined at Months 3, 6 and 12 post‐transplantation. Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T, and CYP3A5 6986G>A. Data on rejection and tacrolimus‐related nephrotoxicity and post‐transplant diabetes mellitus were collected. RESULTS: Correlations between [Tac](blood) and [Tac](cells) were moderate to poor (Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The [Tac](cells)/[Tac](blood) ratio was stable over time in most patients (median intra‐patient variability 39.0%; range 3.5%–173.2%). Age, albumin and haematocrit correlated with the [Tac](cells)/[Tac](blood) ratio. CYP3A5 and CYP3A4 genotype combined affected both dose‐corrected [Tac](blood) and [Tac](cells). ABCB1 was not significantly related to tacrolimus distribution. Neither [Tac](blood) nor [Tac](cells) correlated with clinical outcomes. CONCLUSIONS: The correlation between [Tac](blood) and [Tac](cells) is poor. Age, albumin and haematocrit correlate with the [Tac](cells)/[Tac](blood) ratio, whereas genetic variation in ABCB1, CYP3A4 and CYP3A5 do not. Neither [Tac](blood) nor [Tac](cells) correlated with clinical outcomes. John Wiley and Sons Inc. 2020-11-24 2021-04 /pmc/articles/PMC8056738/ /pubmed/33025649 http://dx.doi.org/10.1111/bcp.14585 Text en © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Francke, Marith I. Hesselink, Dennis A. Li, Yi Koch, Birgit C.P. de Wit, Lucia E.A. van Schaik, Ron H.N. Yang, Lin Baan, Carla C. van Gelder, Teun de Winter, Brenda C.M. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
title | Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
title_full | Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
title_fullStr | Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
title_full_unstemmed | Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
title_short | Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
title_sort | monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056738/ https://www.ncbi.nlm.nih.gov/pubmed/33025649 http://dx.doi.org/10.1111/bcp.14585 |
work_keys_str_mv | AT franckemarithi monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT hesselinkdennisa monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT liyi monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT kochbirgitcp monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT dewitluciaea monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT vanschaikronhn monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT yanglin monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT baancarlac monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT vangelderteun monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients AT dewinterbrendacm monitoringthetacrolimusconcentrationinperipheralbloodmononuclearcellsofkidneytransplantrecipients |